Nevertheless, at the beginning of the COVID-19 pandemic, ACE2 inhibitors or angiotensin receptor blockers, already used for treatment of hypertension, were discussed to have negative effects in COVID-19 patients (Fang et al., 2020; Hammoud et al., 2021), as the treatment leads to an increase in ACE2 expression levels (Hoffmann et al., 2020). This evidence concerns the gene ACE2 and hypertensive disorder.